US pharmaceutical company Moderna Inc (Nasdaq:MRNA) expects to report data from its COVID-19 vaccine trial in children aged two to five years in March 2022, Reuters news agency reported on Thursday.
According to Moderna, if the data is supportive and subject to regulatory consultation, it may then proceed with regulatory filings for children in this age group.
Moderna's mRNA COVID-19 vaccine is already authorised in Europe, the UK, Australia and Canada for adolescents aged 12 to 17 years.
In the United States, the Moderna vaccine is authorised by Food and Drug Administration as primary two-dose regimen and booster dose for adults 18 years and older. The company is yet to get authorisation from the US regulator for use of its vaccine in children.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV